Laboratory Ownership
| LH Stock | USD 239.68 0.75 0.31% |
Shares in Circulation | First Issued 1988-03-31 | Previous Quarter 84.4 M | Current Value 84.2 M | Avarage Shares Outstanding 88 M | Quarterly Volatility 36 M |
Laboratory |
Laboratory Stock Ownership Analysis
About 96.0% of the company shares are owned by institutional investors. The book value of Laboratory was now reported as 96.55. The company has Price/Earnings To Growth (PEG) ratio of 0.49. Laboratory recorded earning per share (EPS) of 8.84. The entity last dividend was issued on the 27th of February 2025. The firm had 1164:1000 split on the 3rd of July 2023. Laboratory Corporation of America Holdings operates as a global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. The company was incorporated in 1994 and is headquartered in Burlington, North Carolina. Laboratory Corp operates under Diagnostics Research classification in the United States and is traded on New York Stock Exchange. It employs 75000 people. To find out more about Laboratory of contact Paul Kirchgraber at 336 229 1127 or learn more at https://www.labcorp.com.Besides selling stocks to institutional investors, Laboratory also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Laboratory's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Laboratory's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Laboratory Quarterly Liabilities And Stockholders Equity |
|
Laboratory Insider Trades History
Less than 1% of Laboratory of are currently held by insiders. Unlike Laboratory's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Laboratory's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Laboratory's insider trades
Laboratory Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Laboratory is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Laboratory of backward and forwards among themselves. Laboratory's institutional investor refers to the entity that pools money to purchase Laboratory's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Dimensional Fund Advisors, Inc. | 2024-12-31 | 1.4 M | Jpmorgan Chase & Co | 2024-12-31 | 1.3 M | Veritas Investment Partners (uk) Ltd. | 2024-12-31 | 1.2 M | Amundi | 2024-12-31 | 1.1 M | Amvescap Plc. | 2024-12-31 | 1.1 M | Nordea Investment Mgmt Bank Demark A/s | 2024-12-31 | 1.1 M | Norges Bank | 2024-12-31 | 1 M | Alliancebernstein L.p. | 2024-12-31 | 1 M | Northern Trust Corp | 2024-12-31 | 1 M | Vanguard Group Inc | 2024-12-31 | 9.7 M | Blackrock Inc | 2024-12-31 | 9.3 M |
Laboratory Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Laboratory insiders, such as employees or executives, is commonly permitted as long as it does not rely on Laboratory's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Laboratory insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Laboratory's latest congressional trading
Congressional trading in companies like Laboratory, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Laboratory by those in governmental positions are based on the same information available to the general public.
| 2024-09-02 | Representative John James | Acquired Under $15K | Verify | ||
| 2020-08-12 | Senator James Inhofe | Acquired $50K to $100K | Verify | ||
| 2019-05-03 | Senator James Inhofe | Acquired $50K to $100K | Verify |
Laboratory Outstanding Bonds
Laboratory issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Laboratory uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Laboratory bonds can be classified according to their maturity, which is the date when Laboratory of has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Laboratory Corporate Filings
F4 | 7th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10K | 25th of February 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
8K | 6th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 3rd of December 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Currently Active Assets on Macroaxis
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Laboratory of. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Laboratory. If investors know Laboratory will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Laboratory listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.05) | Dividend Share 2.88 | Earnings Share 8.84 | Revenue Per Share | Quarterly Revenue Growth 0.098 |
The market value of Laboratory is measured differently than its book value, which is the value of Laboratory that is recorded on the company's balance sheet. Investors also form their own opinion of Laboratory's value that differs from its market value or its book value, called intrinsic value, which is Laboratory's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Laboratory's market value can be influenced by many factors that don't directly affect Laboratory's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Laboratory's value and its price as these two are different measures arrived at by different means. Investors typically determine if Laboratory is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Laboratory's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.